Results 141 to 150 of about 11,461 (257)

Hidradenitis suppurativa

open access: yes, 2018
Hidradenitis suppurativa (HS), is a chronic disease with inflammatory changes in areas with apocrine glands. The disease presents as inflammatory nodules, abscesses, draining tunnels and scarring.
Pasternack, R. (Rafael)   +1 more
core  

Surgical Procedures and Medical Treatments Among Patients With Hidradenitis Suppurativa Before and After Referral to Specialised Dermatological Hospital Care: A Nationwide Registry Study

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 510-516, June 2026.
Hidradenitis suppurativa (HS) is often diagnosed late, complicating management. In this nationwide Danish study including 10,196 patients with dermatologist‐verified HS, we examined treatment patterns before and after referral to specialised hospital care.
Nana A. L. Rosenø   +8 more
wiley   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 651-655, June 2026.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos   +2 more
wiley   +1 more source

Interventions for hidradenitis suppurativa

open access: yes
Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that presents with inflammatory nodules, abscesses, sinus tracts, and scarring with predilection for intertriginous regions.
Robert Boyle   +10 more
core  

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 627-631, June 2026.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin   +4 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender   +2 more
wiley   +1 more source

Ethnicity and Hidradenitis Suppurativa [PDF]

open access: yesJournal of Investigative Dermatology, 2014
Reeder, Virginia J.   +2 more
openaire   +2 more sources

Overall Cumulative Burden of Hidradenitis Suppurativa: An In‐Depth Qualitative Examination

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 551-557, June 2026.
This qualitative study examined the cumulative burden of Hidradenitis Suppurativa (HS) through in‐depth cross‐sectional interviews with 40 patients. The thematic analysis revealed five major concepts: challenging choices, prevalent negative emotions (fear, anxiety, depression), companionship (social support/isolation), life being ‘on hold’ due to ...
Burhan A. Buttar   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy